NCT06684197View on ClinicalTrials.gov

The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption

NANot yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
DexmedetomidineTotal Intravenous AnesthesiaRemifentanil ConsumptionRemifentanilLaparoscopic Abdominal Surgery
Interventions
DRUG

Dexmedetomidine

Intravenous dexmedetomidine will be given as a bolus (0.5 μg.kg-1) over 10 minutes. A perfusion of 0.5 mcg.kg-1.h-1 of dexmedetomidine will be programmed and maintained up until the pneumoperitoneum is deflated or up until a total dose of 2.5μg.kg-1 has been administered.

DRUG

Placebo

Saline will be used instead of dexmedetomidine

Trial Locations (1)

H1T2M4

Hôpital Maisonneuve-Rosemont, Montreal

All Listed Sponsors
lead

Ciusss de L'Est de l'Île de Montréal

OTHER

NCT06684197 - The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption | Biotech Hunter | Biotech Hunter